Celgene to pay Mylan $62 Million to Resolve Cancer Drug Antitrust Case

Reuters - Mylan NV says Celgene Corp will pay it $62 million to resolve a lawsuit alleging the drugmaker improperly stifled competition for its cancer treatment drugs Thalomid and Revlimid by preventing generic versions from entering the market.

Mylan disclosed the settlement in a filing with the U.S. Securities and Exchange Commission on Monday, days after Celgene agreed to pay $55 million to resolve a related class action lawsuit in federal court in Newark, New Jersey.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.